Our findings thus suggest that the pharmacological activation of the adiponectin-AMPK-FOXO-signaling pathway may be therapeutically beneficial in counteracting NAFLD/NASH, consistent with other proposals24, 25. Here, PRKAA1 is linked to metabolic dysfunction-associated steatohepatitis.